Evaluation of the degree of satisfaction in oocyte donors using sustained-release FSH corifollitropin α

Ovarian stimulation treatment is recognized as placing a physical and psychological burden on patients and oocyte donors. The introduction of sustained follicle stimulants will reduce the number of injections and may improve the overall patient experience. This study aimed to evaluate the degree of satisfaction in oocyte donors undergoing treatment with corifollitropin α, a synthetic recombinant rFSH which replaces daily FSH injections for the first week of ovarian stimulation. The results showed no significant differences in clinical parameters between the two protocols (recombinant FSH versus corifollitropin α). Implantation rates for the corifollitropin α and daily FSH protocol groups were 39.1% and 38.4%, respectively, while ongoing pregnancy rates were 45.9% and 44.4%. There were no statistical between-group differences in the responses to the questionnaires. However, donors treated with corifollitropin α who had undergone a previous cycle with daily FSH reported greater satisfaction with the corifollitropin α protocol. In conclusion, no significant differences were found in any analysed parameters between treatments. However, when donors who had undergone both treatments chose which treatment they preferred, the results clearly showed a positive trend towards choosing corifollitropin α, confirming that this protocol may reduce treatment burden and increase donor compliance.Infertility is a stressful situation for couples trying to conceive and has both societal and personal consequences. IVF treatment offers a hopeful solution to many infertile couples; however, the stress of infertility can be increased by IVF treatment, which is a complex process that is both physically and emotionally demanding. There is a clear need for simplified treatment approaches to lessen the treatment burden of IVF. One of the improvements to shorten treatment duration and decrease the number of injections has been the introduction of corifollitropin α, a long-acting recombinant FSH. A single injection of this drug can replace daily gonadotrophin injections for 7 days and can further decrease the number of injections in an ovarian stimulation cycle. In this study, we report an evaluation of the degree of satisfaction in oocyte donors undergoing treatment with corifollitropin α, compared with patients being treated with daily follitropin β. Through some questionnaires being offered to donors after oocyte retrieval, we tried to establish if there were any links between this novel treatment and a lower degree of discomfort suffered during the whole treatment.